LexDanaLexDanabeta
Inventor

Gerald McMahon

Inventor
Kenwood, CA, US

Overview

72→
Patents
1997–2020
Patent span
Chemistry
Primary field (CPC C)

Patents· 72 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Dprimary
C07DHeterocyclic compounds44%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations25%
A61KPreparations for medical, dental or toiletry purposes15%
C07CAcyclic or carbocyclic compounds6%
C07KPeptides5%
G01NInvestigating or analysing materials by determining their chemical or physical properties5%
G06FElectric digital data processing1%
PatentTitleYear
10,774,146Treatment of eosinophil or mast cell related disorders202010,239,943Treatment of eosinophil or mast cell related disorders20197,211,600'Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds'20077,202,265'Indolinone combinatorial libraries and related products and methods for the treatment of disease'20077,189,721'Bicyclic protein kinase inhibitors'20077,119,090'Pyrrole substituted 2-indolinone protein kinase inhibitors'20066,987,113'Tyrosine kinase inhibitors'20066,911,446'Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds'20056,908,930'4-substituted 7-AZA-indolin-2-ones and their use as protein kinase inhibitors'20056,906,093'Indolinone combinatorial libraries and related products and methods for the treatment of disease'20056,855,723'Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds'20056,849,641'Azaindole tyrosine kinase inhibitors'20056,727,252'Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds'20046,696,448'3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors'20046,696,463'3-heteroarylidenyl-2-azaindolinones active as protein tyrosine kinase inhibitors'20046,689,806'Indolinone compounds as kinase inhibitors'20046,683,082'Bicyclic protein kinase inhibitors'20046,660,763'Bis-indolylquinone compounds'20036,656,940'Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors'20036,649,635'Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders'20036,610,688'4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors'20036,596,772'Phosphate mimics and methods of treatment using phosphatase inhibitors'20036,569,868'2-indolinone derivatives as modulators of protein kinase activity'20036,506,763'3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity'20036,486,185'3-heteroarylidene-2-indolinone protein kinase inhibitors'20026,469,032'3-(4-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease'20026,395,734'Pyrrole substituted 2-indolinone protein kinase inhibitors'20026,376,529'Mono- and bis-indolylquinones and prophylactic and therapeutic uses thereof'20026,350,754'3-(cycloalkanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors'20026,329,375'Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors'20016,316,429'Bicyclic protein kinase inhibitors'20016,316,479'Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders'20016,316,635'2-indolinone derivatives as modulators of protein kinase activity'20016,313,158'Bioavailability of 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors'20016,239,161'Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions'20016,225,346'Tyrphostin like compounds'20016,225,335'3-(4\'-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease'20016,204,267'Methods of modulating serine/thereonine protein kinase function with quinazoline-based compounds'20016,180,631'Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds'20016,147,106'Indolinone combinatorial libraries and related products and methods for the treatment of disease'20006,143,765'Pharmaceutical compositions and methods for modulating signal transduction'20006,133,305'3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity'20006,130,238'3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors'20006,114,371'3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors'20006,103,728'Quinazolines'20006,093,728'Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds'20006,090,838'Methods and compositions for inhibition of adaptor protein/tyrosine kinase interactions'20006,051,593'3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors'20006,004,967'Psoriasis treatment with quinazoline compounds'19995,981,569'Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease'19995,935,993'Tyrphostin like compounds'19995,891,917'Certain acrylonitrile-sulfonamide derivatives'19995,886,020'3-(4\'-dimethylaminobenzylidenyl)-2-indolinone and analogues thereof for the treatment of disease'19995,886,195'Thienyl compounds for inhibition of cell proliferative disorders'19995,883,116'3-(2\'-alkoxybenzylidenyl)-2-indolinone and analogues thereof for the treatment of disease'19995,883,113'3-(4\'-Bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease'19995,883,110'Pharmaceutical compositions and methods for modulating signal transduction'19995,880,141'Benzylidene-Z-indoline compounds for the treatment of disease'19995,849,742'Compounds for the treament of disorders related to vasculogenesis and/or angiogenesis'19985,834,504'3-(2\'-halobenzylidenyl)-2-indolinone compounds for the treatment of disease'19985,798,374'Methods of inhibiting phosphatase activity and treatment of disorders associated therewith'19985,792,771'Quinazoline compounds and compositions thereof for the treatment of disease'19985,792,783'3-heteroaryl-2-indolinone compounds for the treatment of disease'19985,780,496'Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions'19985,773,459'Urea- and thiourea-type compounds'19985,763,441'Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis'19985,763,470'Benzopyran compounds and methods for their use'19985,712,395'Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis'19985,710,173'Thienyl compounds for inhibition of cell proliferative disorders'19985,650,415'Quinoline compounds'19975,614,642'Methods of inhibiting phosphatase activity and treatment of disorders associated therewith using naphthopyrones and derivatives thereof'19975,602,171'Methods of inhibiting phosphatase activity and treatment of disorders associated therewith using naphthopyrones and derivatives thereof'1997

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1997–2007Patents assigned to SUGEN INC (64)· patent assignee history
1997–2007Based in Kenwood, CA, US· patent location history
1998–1999Patents assigned to YISSUM RES DEV CO (5)· patent assignee history
1998–2007Based in San Francisco, CA, US· patent location history
2000–2001Patents assigned to ASTA MEDICA AG (2)· patent assignee history
2019–2020Patents assigned to CELLDEX THERAPEUTICS INC (2)· patent assignee history
2019Patents assigned to KOLLTAN PHARMACEUTICALS INC (1)· patent assignee history
2019–2020Based in Westport, CT, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
SUGEN INC641997–2007
YISSUM RES DEV CO51998–1999
ASTA MEDICA AG22000–2001
CELLDEX THERAPEUTICS INC22019–2020
KOLLTAN PHARMACEUTICALS INC12019
Locations
LocationPatentsSpan
Kenwood, California, US441997–2007
San Francisco, California, US261998–2007
Westport, CT, US22019–2020